tetano
Editor, Senior Moderator
PLoS One
. 2024 Jul 29;19(7):e0303113.
doi: 10.1371/journal.pone.0303113. eCollection 2024. Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles
Jennifer Serwanga[SUP] 1 2 [/SUP], Gerald Kevin Oluka[SUP] 1 2 [/SUP], Claire Baine[SUP] 2 [/SUP], Violet Ankunda[SUP] 2 [/SUP], Jackson Sembera[SUP] 2 [/SUP], Laban Kato[SUP] 1 [/SUP], Joseph Ssebwana Katende[SUP] 1 2 [/SUP], Geoffrey Odoch[SUP] 1 2 [/SUP], Betty Oliver Auma[SUP] 1 2 [/SUP], Ben Gombe[SUP] 1 [/SUP]; COVID-19 Immunoprofiling Team; Monica Musenero[SUP] 3 [/SUP], Pontiano Kaleebu[SUP] 1 2 [/SUP]
Affiliations
Understanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine in 67 Ugandans, categorised by prior infection and baseline S-IgG histories: uninfected and S-IgG-negative (n = 12); previously infected yet S-IgG-negative (n = 17); and previously infected with S-IgG-positive status (n = 38). Antibody dynamics were compared across eight timepoints from baseline till nine months. S-IgG antibodies remained consistently potent across all groups. Individuals with prior infections maintained robust S-IgG levels, underscoring the endurance of hybrid immunity. In contrast, those without prior exposure experienced an initial surge in S-IgG after the primary dose but no subsequent significant increase post-boost. However, they reached levels parallel to the previously exposed groups. S-IgM levels remained moderate, while S-IgA persisted in individuals with prior antigen exposure. ChAdOx1-S, Covishield vaccine elicited robust and sustained antibody responses in recipients, irrespective of their initial immune profiles. Hybrid immunity showed higher responses, aligning with global observations. Early post-vaccination antibody levels could predict long-term immunity, particularly in individuals without virus exposure. These findings can inform vaccine strategies and pandemic management.
. 2024 Jul 29;19(7):e0303113.
doi: 10.1371/journal.pone.0303113. eCollection 2024. Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles
Jennifer Serwanga[SUP] 1 2 [/SUP], Gerald Kevin Oluka[SUP] 1 2 [/SUP], Claire Baine[SUP] 2 [/SUP], Violet Ankunda[SUP] 2 [/SUP], Jackson Sembera[SUP] 2 [/SUP], Laban Kato[SUP] 1 [/SUP], Joseph Ssebwana Katende[SUP] 1 2 [/SUP], Geoffrey Odoch[SUP] 1 2 [/SUP], Betty Oliver Auma[SUP] 1 2 [/SUP], Ben Gombe[SUP] 1 [/SUP]; COVID-19 Immunoprofiling Team; Monica Musenero[SUP] 3 [/SUP], Pontiano Kaleebu[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39074077
- DOI: 10.1371/journal.pone.0303113
Understanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine in 67 Ugandans, categorised by prior infection and baseline S-IgG histories: uninfected and S-IgG-negative (n = 12); previously infected yet S-IgG-negative (n = 17); and previously infected with S-IgG-positive status (n = 38). Antibody dynamics were compared across eight timepoints from baseline till nine months. S-IgG antibodies remained consistently potent across all groups. Individuals with prior infections maintained robust S-IgG levels, underscoring the endurance of hybrid immunity. In contrast, those without prior exposure experienced an initial surge in S-IgG after the primary dose but no subsequent significant increase post-boost. However, they reached levels parallel to the previously exposed groups. S-IgM levels remained moderate, while S-IgA persisted in individuals with prior antigen exposure. ChAdOx1-S, Covishield vaccine elicited robust and sustained antibody responses in recipients, irrespective of their initial immune profiles. Hybrid immunity showed higher responses, aligning with global observations. Early post-vaccination antibody levels could predict long-term immunity, particularly in individuals without virus exposure. These findings can inform vaccine strategies and pandemic management.